Immuron Ltd — Regulatory Filings 2009

Aug 30, 2009

Immuren

ABN: 80 063 114 045 Level 1, 39 Leveson Street North Melbourne, VIC 3051 Tel: +61 3 9018 4880 Fax: +61 3 9018 4881

www.immuron.com

31 August 2009

The Manager The Company Announcement Office Australian Stock Exchange Limited Sydney NSW

Dear Sir

Attached is the Appendix 4E in respect of the Results for Announcement to the Market.

Yours faithfully

Graeme Stevens Company Secretary Immuron Limited

÷,

V

Immuron Limited Year ended 30 June 2009 Results for Announcement to the Market

Revenue from continuing operations	Up	72.5%	Тo	550,928
(Loss) from continuing operations after tax attributable to members	Down	13.1%	To	(2,549,959)
Net (loss) for the period attributable to members of Immuron Limited	Down	21.5%	To	(2, 242, 814)

Dividends/distributions	Amount per security	Franked amount per security
Final dividend	NIL	NIL
Interim dividend	NIL	NIL

Record date for determining entitlements to the dividend

$N/A$

A summary of the loss attributable to members of Immuron Limited for the year ended 30 June 2009 is as follows

	\$'000	\$'000
	2009	2008
Income
Income from sale of goods and interest received Grants received	551 320	319 766
Total Income	871	1085
Expenses	(3, 421)	(4, 289)
Loss before income tax	(2,550)	(3,204)
Income tax benefit		268
Loss from continuing operations	(2,550)	(2,936)
Profit from discontinuing operations	307	78
Loss attributable to members of Immuron Limited	(2, 243)	(2.858)

Income

The major increase in the revenues from the sale of goods was from the initial sale of bulk Travelan powder to Alaven Consumer Healthcare (Alaven) in the United States for the production of Travelan™ capsules under the terms of the licence agreement with Alaven.

In respect of the income from tied government grants income there has been a reduction of \$446,000 as a number of projects have either been completed or are close to reaching their completion date. Our major influenza project has received ongoing funding through the recently announced ARC Linkage grant with the University of Melbourne.

Expenses

Expenses decreased overall by \$868,000 with the main variations being in the following categories:

Research & Development

With the reduced level of R & D activity within Australia there has been a reduction in employee costs of approximately \$208,000, together with a reduced requirement for consultants and other costs directly linked to the R $\&$ D projects. Offsetting the reductions in the level of local R & D, there has been an increase in the R & D activities being conducted overseas with two clinical trials being conducted in Israel, together with the costs associated with acquiring the intellectual property from Hadasit. These costs amounted to \$213,000 in the current financial year.

Other expenses

There has also been a significant reduction in general corporate and marketing expenses due partly to the sale of the manufacturing business in the 2008 financial year that were not directly attributable to that business. The major savings in this area has been associated with outside consultants, which have reduced by \$176,000, a reduction in direct product and marketing expenses of \$148,000, together with a reduction in personnel costs of \$304,000 directly related to product marketing.